You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

260 Results
Drug
Other Name(s): Poteligeo®
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Mar 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Mar 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab and Relatlimab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Guidelines and Advice
Regimen
Cancer Type:
Hematologic, 
Myelofibrosis
Intent: Palliative
Funding:
Exceptional Access Program
    momelotinib - For the treatment of splenomegaly and/or disease-related symptoms of myelofibrosis, according to specific criteria

Pages